This inventor holds 3 USPTO granted patents and 10 published patent applications and 2 EPO patents. Top assignee: University of California. Active years: 2021-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Oakland, CA (US) (2021)
- Los Angeles, CA (US) (2023)
Company Filing History:
Years Active: 2021-2025
Title: Innovations of Yvonne Yu-Hsuan Chen in Cancer Treatment
Introduction: Yvonne Yu-Hsuan Chen is a prominent inventor based in Oakland, CA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic methods.
Latest Patents: Yvonne holds 3 patents, with her latest patent focusing on "Chimeric Antigen Receptors and Related Methods and Compositions for the Treatment of Cancer." This patent includes methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments. The disclosed compositions comprise an isolated chimeric interleukin 6 receptor alpha (IL-6Rα) binding protein or cells expressing this protein. These innovations may be utilized in methods of treating cancer and reducing the risk of cytokine release syndrome.
Career Highlights: Yvonne is affiliated with the University of California, where she continues to advance her research in cancer therapies. Her work has garnered attention for its potential impact on improving treatment outcomes for cancer patients.
Collaborations: Yvonne collaborates with notable colleagues, including Meng-Yin Lin and Laurence Chen, who contribute to her research endeavors.
Conclusion: Yvonne Yu-Hsuan Chen's innovative work in cancer treatment exemplifies the vital role of inventors in advancing medical science. Her patents and research efforts are paving the way for new therapeutic approaches in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile